AGC Asahi Glass, a manufacturer of glass, chemicals and high-tech materials, has entered into an agreement to acquire CMC Biologics, a biologics active pharmaceutical ingredient (API) manufacturer, for approximately 60 billion Japanese yen. The agreement, subject to customary approvals, is expected to be completed in January 2017. CMC is CDMO offering biologic API-manufacturing service with mammalian and microbial hosts. The company provides cell line construction, process development, scale...